Drugs / HLD200
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02520388 | Aug 2015 → Apr 2016 | attention deficit-hyperactivity disorder | Ironshore Pharmaceuticals and Development, Inc | Completed | Missed primary |
| Phase 3 | NCT02255513 | May → Oct 2014 | attention deficit-hyperactivity disorder | Ironshore Pharmaceuticals and Development, Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLD200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02255513 ↗ |
| Route | Oral | “HLD200 was administered orally” NCT02255513 ↗ |